Long-term continuous methimazole or radioiodine treatment for hyperthyroidism

Archives of Iranian Medicine

Volumn 15, Issue 8, 2012, Pages 477-484

  Azizi, Fereidoun ^a   Yousefi, Vahid ^a   Bahrainian, Abdolmajid ^a   Sheikholeslami, Farhad ^a   Tohidi, Maryam ^a   Mehrabi, Yadollah ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antithyroid drugs; Hyperthyroidism; Methimazole; Radioactive iodine

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVOTHYROXINE; LIPID; LIPOPROTEIN; RADIOACTIVE IODINE; THIAMAZOLE; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE DENSITY; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; DIASTOLE; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FUNCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTELLIGENCE QUOTIENT; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL DISEASE; MOOD; NEUROPSYCHOLOGICAL TEST; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THYROID DISEASE; THYROID FUNCTION; TOXIC GOITER;

ANTITHYROID AGENTS; FEMALE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; METHIMAZOLE; MIDDLE AGED; TIME FACTORS;

EID: 84864760782     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Eng J Med. 2001; 344: 501-509.
2. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005, 294: 71-80.
3. Metso S, Auvinen A, Salmi J, Huhtala H, Jaatinen P. Increased longterm cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin Endocrinol (Oxf). 2008, 68: 450-457.
4. Franklyn JA. Is radioiodine good for hyperthyroidism? Nat Clin Pract Endocrinol Metab. 2008, 4: 59.
5. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007, 92: 2190-2196.
6. Holm LE. Changing annual incidence of hypothyroidism after 131I therapy for hyperthyroidism, 1951-1975. J Nucl Med. 1982; 23: 108-112.
7. Canaris GJ, Manowitz NR, Mayor G, Chester R.E. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160: 526-534.
8. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, mood, and cognition in experimentally induced subclinical hypothyroidism. J Clin Endocrinol Metab. 2007; 92: 2545-2551.
9. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010; 304: 1365-1374.
10. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994; 331: 1249-1252.
11. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994; 130: 350-356.
12. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Europ J Endocrinol. 2005; 152: 695-701.
13. Ainsworth BE, Jacobs DR Jr, Leon AS. Validity and reliability of selfreported physical activity status: the Lipid Research Clinics questionnaire. Med Sci Sports Exerc. 1993; 25: 92-98.
14. Zulewski H, Müller B, Exer P, Miserez AR, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997; 82: 771-776.
15. Crooks J, Murray IPC, Wayne EJ. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med. 1959; 28: 110.
16. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA. 1989; 262: 907-913.
17. Lezak MD, Howieson DB, Loring DW, Julia Hannay H, Fisher JS. Neuropsychological Assessment. 4th ed. New York: Oxford University Press; 2004.
18. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009; 22: 107-133.
19. Kendall-Taylor PK, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long terms follow up study. Brit Med J. 1984; 28: 9361-9363.
20. Sridama A, McCormick M, Kaplan EL, Fauchet R, DeGrool LJ. Longterm follow up study of compensated low dose 13I therapy. New Engl J Med. 1984; 311: 426-432.
21. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002; 57: 577-585.
22. Sato K, Han DC, Fujii Y, Tsushima T, Shizume K. Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3, 5, 3'- triiodo-L-thyronine nuclear receptors. Endocrinology. 1987; 120: 1873-1881.
23. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyrodism. J Clin Endocrinol Metab. 2000; 85: 4157-4161.
24. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and moneral metabolism. Endocrinol Metab Clin North Am. 1990; 19: 35-63.
25. Trochon V, Blot E, Cymbalista F, Engelmann C, Tang RP, Thomaïdis A, et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eurpean J Endocrinol. 2001; 145: 691-696.
26. Faber J, Petersen L, Wiinberg N, Schifter S, Mehlsen J. Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. Thyroid. 2002; 12: 319-324.
27. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008; 158: 69-75.
28. Solomon B, Glinoer D, lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab. 1990; 70: 1518-1524.
29. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid. 1991; 1: 129-135.
30. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990; 70: 675-679.